AP02
Idiopathic Pulmonary Fibrosis (IPF)
Phase 2Active
Key Facts
About Avalyn Pharmaceuticals
Avalyn Pharma is a private, clinical-stage biotech focused on transforming the treatment of rare lung diseases through localized inhaled drug delivery. Its pipeline features two Phase 2 assets, AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib), and a preclinical fixed-dose combination, AP03, aiming to improve upon the tolerability limitations of current oral therapies. Led by an experienced team with deep respiratory and corporate development expertise, the company has raised over $275 million from a syndicate of top-tier life science investors. Avalyn is positioned to address a significant unmet need in a market with established systemic therapies but substantial side-effect burdens.
View full company profileOther Idiopathic Pulmonary Fibrosis (IPF) Drugs
| Drug | Company | Phase |
|---|---|---|
| Axatilimab (SNDX-6352) | Syndax Pharmaceuticals | Phase 2 |
| PIPE-791 | Contineum Therapeutics | Phase 1 |
| LYT-100 (Deupirfenidone) | PureTech Health | Phase 2b |
| Bexotegrast (PLN-74809) | Pliant Therapeutics | Phase 2b |
| TTI-101 | Tvardi Therapeutics | Phase 2 |
| Gento-Fibrose Pulmonaire Program | Genoscience Pharma | Preclinical |
| SM001 (alidornase/Tigerase) | SarcoMed USA | Research |